Advertisement

Topics

Primary Immune Deficiency (PID) - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Primary Immune Deficiency (PID) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 67-page report is available in PDF from $2000.

Primary Immune Deficiency (PID) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Primary Immune Deficiency (PID) - Pipeline Review, H1 2015’, provides an overview of the Primary Immune Deficiency (PID)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Primary Immune Deficiency (PID), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Immune Deficiency (PID) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Primary Immune Deficiency (PID) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Primary Immune Deficiency (PID) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Primary Immune Deficiency (PID) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Primary Immune Deficiency (PID) Overview 8
Therapeutics Development 9
Pipeline Products for Primary Immune Deficiency (PID) - Overview 9
Pipeline Products for Primary Immune Deficiency (PID) - Comparative Analysis 10
Primary Immune Deficiency (PID) - Therapeutics under Development by Companies 11
Primary Immune Deficiency (PID) - Therapeutics under Investigation by Universities/Institutes 12
Primary Immune Deficiency (PID) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Primary Immune Deficiency (PID) - Products under Development by Companies 16
Primary Immune Deficiency (PID) - Products under Investigation by Universities/Institutes 17
Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development 18
ADMA Biologics, Inc. 18
Genethon 19
GlaxoSmithKline plc 20
Green Cross Corporation 21
Octapharma AG 22
ProMetic Life Sciences Inc. 23
Sangamo BioSciences, Inc. 24
Sanofi 25
Primary Immune Deficiency (PID) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(immune globulin (human) + hyaluronidase (recombinant)) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Gene Therapy for Severe Combined Immune Deficiency - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Gene Therapy for X-Linked SCID - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Gene Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
GSK-2696273 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
immune globulin (human) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
immune globulin (human) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NewNorm - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
OT-81 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
plerixafor - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RI-002 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
For more information open Primary Immune Deficiency (PID) - Pipeline Review, H1 2015.

SKU: GMDHC6614IDB

Original Article: Primary Immune Deficiency (PID) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Primary Immune Deficiency (PID) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...